Beijing Jiluntai Pharmaceutical

Beijing Jiluntai Pharmaceutical Co., Ltd. is a clinical-stage nuclear medicine innovation company focused on developing targeted diagnostic and therapeutic radiopharmaceuticals (theranostics). Founded by Professor Wang Fan of Peking University and incubated by Baheal Pharma Group, the company leverages its proprietary radiopharmaceutical R&D platform to cover isotope labeling, targeted molecule screening, and clinical translation. Jiluntai's lead product, Technetium [99mTc] Pexireotide Peptide Injection (99mTc-3PRGD2), was approved in China in April 2026 as the world's first broad-spectrum tumor imaging agent for SPECT targeting integrin alpha-V beta-3. The company's pipeline also includes therapeutic radiopharmaceuticals like 177Lu-AB-3PRGD2 and diagnostic agents like 99mTc-HP-Ark2 targeting HER2.